<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017003</url>
  </required_header>
  <id_info>
    <org_study_id>MPC-004-07-1004</org_study_id>
    <nct_id>NCT01017003</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study With Colchicine in Healthy Volunteers</brief_title>
  <official_title>An Open Label, Two Period, Sequential, Single Dose and Multiple Dose Pharmacokinetic Study With 0.6mg Colchicine Tablets in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mutual Pharmaceutical Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mutual Pharmaceutical Company, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, single group, sequential dose study will compare the single dose
      pharmacokinetics of colchicine 0.6 mg given orally to colchicine pharmacokinetics after 10
      days of a standard prophylactic dose (0.6 mg every 12 hours) in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open label, single group, sequential dose study will compare the single dose
      pharmacokinetics of colchicine 0.6 mg given orally to colchicine pharmacokinetics after 10
      days of a standard prophylactic dose (0.6 mg every 12 hours) in healthy volunteers. After a
      fast of at least 10 hours, fourteen healthy non-smoking, non-obese, non-pregnant volunteers
      will receive a single oral dose of colchicine 0.6 mg. Fasting will continue for 4 hours after
      the dose, at which time a standard meal will be served. Blood will be drawn from all
      participants at times sufficient to adequately define the single dose pharmacokinetics of
      colchicine and its 3 major metabolites, 2, 3 and 10 demethylcolchicine. Following a 14 day
      washout period, all participants will begin a 10 day regimen of colchicine 0.6 mg orally
      every 12 hours. On the morning of day 25, after a fast of at least 10 hours, all participants
      will receive their final dose of colchicine 0.6 mg. Again blood will be drawn at times
      sufficient to determine the pharmacokinetics of colchicine and its 3 major metabolites after
      chronic dosing. The pharmacokinetic parameters for each dosing situation will be derived and
      compared for relevant differences. Though not a specific goal of this study, all participants
      will be monitored for adverse events by observation and query during periods of confinement
      on days 1, 15 and 25, as well as by complete blood count (CBC) with differential and clinical
      chemistry, sitting and standing blood pressures, and heart rate and 12-lead electrocardiogram
      (EKG) before and after dosing, on days 1 and 25.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>Pharmacokinetic samples collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Time Zero to the Time of the Last Measured Level.</measure>
    <time_frame>0.0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 36, 48, 72, and 96 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-inf)</measure>
    <time_frame>0.0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.6mg colchicine tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>colchicine 0.6mg q12 hours for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine tablets</intervention_name>
    <description>0.6mg colchicine tablet</description>
    <arm_group_label>1</arm_group_label>
    <other_name>COLCRYS TM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>colchicine tablets</intervention_name>
    <description>0.6mg q12 hours for 10 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>COLCRYS TM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of the screening process within 28 days prior to Period I dosing

          -  Healthy non-smoking, non-obese adult men and women volunteers between the ages of 18
             to 45 years of age, weighing at least 110 with a body mass index of 18-30kg/m2

          -  Women must be postmenopausal, surgically sterile, commit to abstinence from
             heterosexual sexual contact or use two methods of contraception.

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Use of any investigational drug within 28 days prior to Period I dosing.

          -  Presence or history of a clinically significant disorder involving the cardiovascular,
             respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or
             neurologic system(s) or psychiatric disease as determined by the clinical
             investigator(s)

          -  Positive screen for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HbsAg), or hepatitis C virus (HCV)

          -  Clinical laboratory test values outside the accepted reference range and when
             confirmed on re-examination.

          -  Any clinically significant illness during the 4 weeks prior to Period I dosing (as
             determined by the clinical investigators)

          -  Use of any systemic prescription medication in the 14 days prior to Period I dosing

          -  History of any allergy(s) including allergy to colchicine or related drugs.

          -  History of drug or alcohol addiction or abuse within the past year or a positive drug
             abuse screen

          -  Currently or recent (within 6 months) use of tobacco products prior to dose
             administration

          -  Donation of greater than 150 mL of blood within 28 days or plasma within 14 days prior
             to period I dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony R Godfrey, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institiute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd. - Cetero Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Recalls, Market Withdrawals and Safety Alerts</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Daily Med - Posting of Recently Submitted Labeling to the FDA</description>
  </link>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2009</study_first_posted>
  <results_first_submitted>August 13, 2009</results_first_submitted>
  <results_first_submitted_qc>October 5, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2009</results_first_posted>
  <last_update_submitted>October 5, 2009</last_update_submitted>
  <last_update_submitted_qc>October 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vice President Branded Products and Medical Affairs</name_title>
    <organization>Mutual Pharmaceutical Company, Inc.</organization>
  </responsible_party>
  <keyword>healthy</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Colchicine - Single Dose, Twice Daily Dose, Final Single Dose</title>
          <description>All subjects received a single dose of colchicine 0.6 mg on Day 1 following an overnight fast. After a 14-day washout period, subjects received colchicine 0.6 mg every 12 hours for 10 days. On the morning of Day 25, subjects received their final colchicine 0.6 mg dose following an overnight fast.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Single Dose Colchicine 0.6 mg, Day 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>14 Day Washout Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Colchicine 0.6 mg Twice Daily x 10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Colchicine 0.6 mg Final Dose</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colchicine - Single Dose, Twice Daily Dose, Final Single Dose</title>
          <description>All subjects received a single dose of colchicine 0.6 mg on Day 1 following an overnight fast. After a 14-day washout period, subjects received colchicine 0.6 mg every 12 hours for 10 days. On the morning of Day 25, subjects received their final colchicine 0.6 mg dose following an overnight fast.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" lower_limit="19" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Serum Concentration (Cmax)</title>
        <description>maximum serum concentration measured after a single oral dose in fasted healthy adults and after a single oral dose in fasted healthy adults at steady state for comparison of the two conditions</description>
        <time_frame>Pharmacokinetic samples collected pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Pharmacokinetics (Day 1)</title>
            <description>0.6mg colchicine orally administered to healthy fasted volunteers as a single isolated dose (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Colchicine Pharmacokinetics at Steady State (Day 25)</title>
            <description>0.6mg colchicine tablet administered to healthy fasted volunteers after a regimen of oral colchicine 0.6mg every 12 hours for 10 days (Day 25)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum Concentration (Cmax)</title>
          <description>maximum serum concentration measured after a single oral dose in fasted healthy adults and after a single oral dose in fasted healthy adults at steady state for comparison of the two conditions</description>
          <population>per protocol</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2450.15" spread="702.11"/>
                    <measurement group_id="O2" value="3553.15" spread="843.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Time Zero to the Time of the Last Measured Level.</title>
        <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (t), calculated using the linear trapezoidal rule.</description>
        <time_frame>0.0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 36, 48, 72, and 96 hours after dosing</time_frame>
        <population>by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Pharmacokinetics (Day 1)</title>
            <description>0.6mg colchicine orally administered to healthy fasted volunteers as a single isolated dose (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Colchicine Pharmacokinetics at Steady State (Day 25)</title>
            <description>0.6mg colchicine tablet administered to healthy fasted volunteers after a regimen of oral colchicine 0.6mg every 12 hours for 10 days (Day 25)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Time Zero to the Time of the Last Measured Level.</title>
          <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (t), calculated using the linear trapezoidal rule.</description>
          <population>by protocol</population>
          <units>pg-h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10494.66" spread="3544.08"/>
                    <measurement group_id="O2" value="43576.96" spread="9333.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-inf)</title>
        <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
        <time_frame>0.0, 0.5, 1,1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, and 96 hours after dosing</time_frame>
        <population>by protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Colchicine Pharmacokinetics (Day 1)</title>
            <description>0.6mg colchicine orally administered to healthy fasted volunteers as a single isolated dose (Day 1)</description>
          </group>
          <group group_id="O2">
            <title>Colchicine Pharmacokinetics at Steady State (Day 25)</title>
            <description>0.6mg colchicine tablet administered to healthy fasted volunteers after a regimen of oral colchicine 0.6mg every 12 hours for 10 days (Day 25)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC 0-inf)</title>
          <description>The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable plasma concentration to the elimination rate constant.</description>
          <population>by protocol</population>
          <units>pg-h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12268.18" spread="4422.08"/>
                    <measurement group_id="O2" value="54198.77" spread="9214.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Colchicine Pharmacokinetics (Day 1)</title>
          <description>0.6mg colchicine orally administered to healthy fasted volunteers as a single isolated dose (Day 1)</description>
        </group>
        <group group_id="E2">
          <title>Colchicine Pharmacokinetics at Steady State (Day 25)</title>
          <description>0.6mg colchicine tablet administered to healthy fasted volunteers after a regimen of oral colchicine 0.6mg every 12 hours for 10 days (Day 25)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomach Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>14 subjects were sought, 13 enrolled due difficult recruitment. It was impossible to determine the kinetics of metabolites because none reached the level of detectability.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Mutual Pharmaceutical Company, Inc.</organization>
      <phone>215-697-1743</phone>
      <email>clinicaltrials@urlmutual.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

